From Delay to Damage

Join us on Tuesday, October 28, 2025 in Chicago, IL or via live stream! Click below for more information and to register.

This symposium is sponsored by Integritas Communications and supported by an educational grant from AstraZeneca. This is not an official program of the American College of Rheumatology. 

There is no fee to attend these educational programs; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.

Target Audience

This activity is intended for rheumatologists and other specialists (eg, pulmonologists, allergists/clinical immunologists) who manage patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune small-vessel vasculitis that has a complex phenotype with symptomatology that affects multiple organ systems. Join us for this engaging Expert Insights program to learn more about EPGA, an intriguing heterogeneous multisystem disease plagued by delays in diagnosis – and the effective targeted biologic therapies that are now available to treat this disease. Along with a whiteboard animation, multidisciplinary faculty will review the pathophysiologic processes underlying EGPA development, best approaches for prompt diagnosis, and strategies for individualizing therapeutic regimens that improve patient outcomes. You don’t want to miss this informative and thought-provoking session!

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Describe the pathophysiologic causes and biopsychosocial consequences of EGPA
2. Identify patients with EGPA quickly based symptoms, laboratory testing, and ruling out other potential disorders
3. Discuss the clinical rationale and trial evidence for biologic treatment options for patients with EGPA
4. Construct biologic-based regimens for patients with EGPA to address underlying pathophysiologic processes, reduce corticosteroid exposure, and target remission